---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-22-012194"
form_type: "8-K"
ticker: "KZR"
cik: "0001645666"
company_name: "Kezar Life Sciences, Inc."
filed_at: "2022-06-27T23:59:59+00:00"
generated_at: "2026-06-24T22:56:42.036835+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Kezar Phase 2 MISSION trial: 64.7% overall renal response rate in lupus nephritis

## Summary
- 11 of 17 patients (64.7%) achieved overall renal response (≥50% reduction in UPCR) at 6 months.
- 6 of 17 patients (35.2%) achieved complete renal response (UPCR ≤0.5, eGFR stable, steroids ≤10 mg/day).
- Zetomipzomib well tolerated; most AEs mild-to-moderate; no Grade 3 infections reported.
- Mean daily prednisone reduced from 19.2 mg at baseline to 9.1 mg at end of treatment.
- Company plans continued development for lupus nephritis and evaluation for systemic lupus erythematosus.

## SEC filing metadata
- accession: 0000950170-22-012194
- form_type: 8-K
- ticker: KZR
- cik: 0001645666
- company_name: Kezar Life Sciences, Inc.
- filed_at: 2022-06-27T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1645666/000095017022012194/0000950170-22-012194-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1645666/000095017022012194/kzr-20220627.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-22-012194
- JSON: https://secwatch.observer/filing/0000950170-22-012194.json
- Plain text: https://secwatch.observer/filing/0000950170-22-012194.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.